BioCardia Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters11-14

* BioCardia Inc reported a quarterly adjusted loss of 61 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.80. The lone analyst forecast for the quarter was for a loss of $1.19 per share.

* Reported revenue was zero; analysts expected $200.00 thousand.

* BioCardia Inc's reported EPS for the quarter was a loss of 61 cents.

* The company reported a quarterly loss of $1.74 million.

* BioCardia Inc shares had fallen by 23.1% this quarter and lost 75.9% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts was unchanged in the last three months.

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for BioCardia Inc is 25.00 This summary was machine generated from LSEG data November 14 at 04:02 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -1.19 -0.61 Beat

Dec. 31 2023 -1.65 -1.35 Beat

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483892642?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-14 12:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483892642","market":"us","top_or_hot":-1,"title":"BioCardia Inc reports results for the quarter ended September 30 - Earnings Summary","media":"Reuters","content":"<html><body><p>* <a href=\"https://laohu8.com/S/BCDA\">BioCardia</a> Inc    reported a quarterly adjusted loss of 61 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.80.  The lone analyst forecast for the quarter was for a loss of $1.19 per share. </p><p>   * Reported revenue was zero; analysts expected $200.00 thousand. </p><p>   * BioCardia Inc's reported EPS for the quarter was a loss of 61 cents.</p><p>   * The company reported a quarterly loss of $1.74 million.</p><p>   * BioCardia Inc shares had fallen by 23.1% this quarter and lost 75.9% so far this year.</p><p>FORECAST CHANGES</p><p>   * The mean earnings estimate of analysts was unchanged in the last three months. </p><p>   * In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</p><p>RECOMMENDATIONS</p><p>   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\" </p><p>   * The average consensus recommendation for the biotechnology &amp; medical research peer group is also \"buy\"</p><p>Wall Street's median 12-month price target for BioCardia Inc is 25.00  This summary was machine generated from LSEG data November 14 at 04:02 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,</p><p>                                                MISSED</p><p>Sep. 30 2024      -1.19          -0.61          Beat</p><p>Dec. 31 2023      -1.65          -1.35          Beat</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioCardia Inc reports results for the quarter ended September 30 - Earnings Summary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioCardia Inc reports results for the quarter ended September 30 - Earnings Summary\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 12:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* BioCardia Inc    reported a quarterly adjusted loss of 61 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.80.  The ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCDA","symbol_name":"BioCardia","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2483892642","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483892642","pubTimestamp":1731556975,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* BioCardia Inc    reported a quarterly adjusted loss of 61 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.80.  The lo","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BCDA":"BioCardia"},"translate_title":"BioCardia Inc报告截至9月30日的季度业绩-收益摘要","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCDA":1},"content_text":"* BioCardia Inc    reported a quarterly adjusted loss of 61 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.80.  The lone analyst forecast for the quarter was for a loss of $1.19 per share.    * Reported revenue was zero; analysts expected $200.00 thousand.    * BioCardia Inc's reported EPS for the quarter was a loss of 61 cents.   * The company reported a quarterly loss of $1.74 million.   * BioCardia Inc shares had fallen by 23.1% this quarter and lost 75.9% so far this year.FORECAST CHANGES   * The mean earnings estimate of analysts was unchanged in the last three months.    * In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.RECOMMENDATIONS   * The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 1 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"    * The average consensus recommendation for the biotechnology & medical research peer group is also \"buy\"Wall Street's median 12-month price target for BioCardia Inc is 25.00  This summary was machine generated from LSEG data November 14 at 04:02 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,                                                MISSEDSep. 30 2024      -1.19          -0.61          BeatDec. 31 2023      -1.65          -1.35          Beat","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483892642"}